Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Business Wire 20-Apr-2026 7:00 AM

nPulse™ Technology highlighted in late-breaking feasibility study and live case transmission

Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois.

At HRS 2026, Pulse Biosciences will present late-breaking clinical trial updates, highlighting European feasibility study one-year outcomes of nanosecond PFA using a compliant catheter for the treatment of atrial fibrillation (AF). The Company will also participate in a live case transmission during the PFA Live Case Summit.

In addition to its booth and technology suite, the proprietary nsPFA™ Technology will be featured at several events at the HRS 2026 Annual Meeting including:

Thursday, April 23, 2026

PFA Live Case Summit – Session II: Live PFA Cases Time: 9:40 a.m. – 11:10 a.m. Location: McCormick Place – Room S406AB

• Live Case Title: PVI+PWA Using Nanosecond PFA
• Case Site: Fakultní nemocnice Motol a Homolka, Prague, Czech Republic
• Case Operators: Jan Petru, MD, and Moritoshi Funasako, MD

This live case will demonstrate the use of Pulse Biosciences' nsPFA™ technology in the treatment of atrial fibrillation, highlighting procedural workflow, lesion delivery, and real-time performance in a clinical setting.

Saturday, April 25, 2026

Late-Breaking Clinical Science Time: 11:45 a.m. – 11:55 a.m. Location: Room S100AB (Plenary Room)

• Presentation: One-year Outcomes of Nanosecond Pulsed Field Ablation Using a Compliant Catheter to Treat Atrial Fibrillation: A Multicenter Experience
• Presenter: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai, New York, NY

This late-breaking presentation will report one-year clinical outcomes from a multicenter experience evaluating nanosecond pulsed field ablation using a compliant catheter to treat atrial fibrillation, contributing important longer-term data to the evolving PFA landscape.

Posters & Oral Abstracts

Presentation | Novel Mapping and Ablation Technologies Date: Friday, April 24, 2026 Time: 1:10 p.m. – 1:20 p.m. Location: Heart Rhythm Hub 3 – South Lobby

• Oral Abstract: Nanosecond Pulsed Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation: A Multicenter Experience
• Presenter: Petr Neuzil, Fakultní nemocnice Motol a Homolka, Prague, Czech Republic

Featured Poster Session I Date: Friday, April 24, 2026 Time: 3:15 p.m. – 5:15 p.m. Location: Abstract Pavilion – Exhibit Hall

• Abstract: Effects of Dose and Catheter Orientation on Focal Nanosecond Pulsed Field Ablation Lesions: A Preclinical Study
• Presenter: Masaya Shinohara, Icahn School of Medicine at Mount Sinai

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company's proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420628292/en/

Investors: Pulse Biosciences, Inc. Jon Skinner, CFO IR@pulsebiosciences.com

Or

Gilmartin Group Philip Trip Taylor 415.937.5406 philip@gilmartinir.com